Cathay Biotech Stock Hits Day Low of CNY 51.90 Amid Price Pressure

Cathay Biotech, Inc., a prominent player in the specialty chemicals sector, experienced a notable decline of 3.16% on March 18, 2026, reaching an intraday low of CNY 51.90. This performance contrasts with the China Shanghai Composite, which saw a slight increase of 0.32% on the same day. Over the past week, Cathay Biotech's stock has decreased by 1.78%, while its performance over the last month shows a decline of 1.21%. In the longer term, the company has faced challenges, with a three-year performance drop of 13.12% and a five-year decline of 8.21%. Despite these setbacks, the company has reported positive results for the last four consecutive quarters, highlighting a return on capital employed (ROCE) of 8.99% and a significant reduction in raw material costs by 15.64% year-over-year. Cathay Biotech's market capitalization stands at CNY 30,966 million, with a price-to-earnings ratio of 71.00 and a dividend yield of 0.75%. The company continues to navigate a competitive landscape, reflecting a complex interplay of financial metrics and market dynamics.